APOA1 and type 2 diabetes mellitus: Meanwhile, the apoA-I addition to plasmas of T2D patients of group 3 (Figure 8A) ameliorated cell viability both 5% v/v and 0.5% v/v of plasmas at 44% and 65% cases respectively.